

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application:

**Listing of Claims:**

1. (original) A method of treating SARS-coronavirus infection, comprising administering an effective amount of an interferon to a patient, wherein the interferon is IFN  $\alpha$ -n1, IFN  $\alpha$ -n3, human leukocyte IFN  $\alpha$  or IFN  $\beta$ -1b.
2. (original) The method of claim 1 wherein the interferon is recombinant.
3. (original) The method of claim 2 wherein the interferon is recombinantly produced in *E. coli*.
4. (original) The method of claim 2 wherein the interferon is recombinantly produced in mammalian cells.
5. (currently amended) The method of ~~any one of claims 1 to 4~~ claim 2 further comprising administering an additional antiviral agent in combination with the interferon.
6. (original) The method of claim 5 wherein the additional antiviral agent is ribavirin.

Claims 7 to 13 (cancelled).

14. (original) A method of inhibiting SARS-coronavirus infection, comprising administering an interferon to a cell capable of being infected with SARS-CoV, wherein the interferon is IFN  $\alpha$ -n1, IFN  $\alpha$ -n3, human leukocyte IFN  $\alpha$  or IFN  $\beta$ -1b.
33. (original) The method of claim 14 wherein the interferon is recombinant.
34. (original) The method of claim 15 wherein the interferon is recombinantly produced in *E. coli*.

35. (original) The method of claim 15 wherein the interferon is recombinantly produced in mammalian cells.

36. (currently amended) The method of ~~any one of claims 14 to 17~~ claim 15 wherein the cell is in a patient.

37. (currently amended) The method of ~~any one of claims 14 to 17~~ claim 15 wherein the cell is a cell in vitro.

38. (original) The method of claim 19 wherein the cell is a VERO 6 cell, a peripheral blood leukocyte or a THP-1 monocyte.

39. (original) The method of ~~any one of claims 14 to 20~~ claim 15 further comprising administering to the cell an additional antiviral agent in combination with the interferon.

40. (original) The method of claim 21 wherein the additional antiviral agent is ribavirin.

Claims 23 to 32 cancelled.

33. (original) A kit comprising an interferon and instructions for using the interferon to treat SARS-coronavirus infection, wherein the interferon is IFN  $\alpha$ -n1, IFN  $\alpha$ -n3, human leukocyte IFN  $\alpha$  or IFN  $\beta$ -1b.

34. (original) A kit comprising an interferon and instructions for using the interferon to inhibit SARS-coronavirus infection, wherein the interferon is IFN  $\alpha$ -n1, IFN  $\alpha$ -n3, human leukocyte IFN  $\alpha$  or IFN  $\beta$ -1b.

35. (currently amended) The kit of claim 33 [[or 34]] wherein the interferon is recombinant.

36. (original) The kit of claim 35 wherein the interferon is recombinantly produced in E. coli.

37. (original) The kit of claim 35 wherein the interferon is recombinantly produced in mammalian cells.

38. (currently amended) The kit of ~~any one of claims 33 to 37~~ claim 35 further comprising an additional antiviral agent.
39. (original) The kit of claim 38 wherein the additional antiviral agent is ribavirin.
40. (new) The kit of claim 34 wherein the interferon is recombinant.
41. (new) The kit of claim 40 wherein the interferon is recombinantly produced in E. coli.
42. (new) The kit of claim 40 wherein the interferon is recombinantly produced in mammalian cells.
43. (new) The kit of claim 40 further comprising an additional antiviral agent.
44. (new) The kit of claim 43 wherein the additional antiviral agent is ribavirin.